Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Pneumothorax Treatment Market size was valued at USD 31.5 billion in 2024 and is likely to cross USD 60.89 billion by 2037, expanding at more than 5.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of pneumothorax treatment is estimated at USD 32.89 billion.
The growth of the market is due to the burgeoning occurrence of pneumothorax inside the worldwide population, due to the high prevalence of lung diseases which includes asthma, COPD, cystic fibrosis, tuberculosis, and many more. For instance, studies display that the prevalence of COPD was predicted to be 10% in 2020 for each male and female, or 480 million cases globally. As a result, the high incidence of pneumothorax infection because of rising lung sicknesses in the global populace necessitates a larger marketplace for related treatment, diagnostics, and preventive measures.
In addition, the rising smoking rate in the population would also support the industry and accelerate its expansion during the projection period. According to data published by the World Health Organization, an estimated 36.7% of males and 7.8% of women worldwide smoked tobacco in 2020, making up 22.3% of the global population.
Pneumothorax Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Geriatric Population: Because of their stagnated bodily organs, there is a higher risk of chronic respiratory disease, particularly after the age of 60, making elderly individuals more vulnerable to pneumothorax infection. According to the United Nations in 2019, there were an estimated 703 million people worldwide who were 65 years of age or older. Furthermore, it stated that the percentage of adults 65 and older is rising faster than that of adults under that age. Thus, the increasing aging population is expected to propel the pneumothorax treatment market in the forecast period.
- Advancement in Medical Technology: Due to technological advancements in medicine, the diagnosis and management of pneumothorax infections have been enhanced, especially in the areas of minimally invasive surgery and imaging. In addition, the use of telemedicine and remote patient monitoring technology presents chances for prompt follow-up therapy and consultation for patients with pneumothorax infections. This can increase adherence to treatment regimens by patients and enable early intervention when needed. These developments increase the pneumothorax treatment market by making them less intrusive, more effective, and requiring shorter recovery times.
- Rising Awareness of Pneumothorax Infection: Due to the rising awareness of pneumothorax infection, the importance of early detection and treatment is increasing rapidly. The increased awareness is fueled by public health campaigns, like the Inspire Chronic Obstructive Pulmonary Disease (COPD) program and the annual World No Tobacco Day campaign to name a few, which raise awareness of respiratory diseases like pneumothorax, asthma, etc., thus contributing to the expansion of the pneumothorax treatment market as people become more aware of the dangers and outcomes associated with pneumothorax.
Challenges
- Difficulties with Diagnosis: It can be difficult to diagnose pneumothorax infection accurately, particularly when the symptoms are mild or there is a lack of accessibility to imaging technology. Inadequate or delayed treatment may result from a misdiagnosis or delayed diagnosis causing hindrance in the market growth.
- Complying with strict regulations regarding new treatments and medical devices for pneumothorax infection can impede pneumothorax treatment market growth.
- Limited awareness regarding pneumothorax treatment in underdeveloped and developing countries can hinder market growth in the forecast period.
Pneumothorax Treatment Market: Key Insights
Pneumothorax Treatment Segmentation
End-user (Hospital, Clinics, Ambulatory Distribution Channel)
The hospital segment in pneumothorax treatment market is estimated to gain a significant share of about ~44% in the year 2037. The availability of hospitals throughout the world and the availability of rapid and simple treatments for pneumothorax infections are both factors contributing to the segment's growth, which is anticipated to fuel market expansion. For reference, the number of hospitals worldwide as of 2021 is estimated to be 165,000. Hospitals are the primary end users in the pneumothorax treatment market, offering therapy, post-treatment care, and assistance for diagnostics to patients infected with pneumothorax.
Type (Primary Spontaneous, Secondary Spontaneous, Latrogenic, Injury Related, Catamenial)
The secondary spontaneous pneumothorax segment in pneumothorax treatment market is estimated to gain the largest revenue share of about ~30% in the year 2037. The segment growth can be attributed to the growing prevalence of persistent lung diseases consisting of bronchial asthma, interstitial lung disease (ILD), cystic fibrosis, or lung cancers. A secondary spontaneous pneumothorax refers to a spontaneous pneumothorax in a patient with preexisting persistent lung ailments. Studies show that around 545 million people worldwide, or 7·4% of the total population, suffer from a chronic respiratory ailment. Furthermore, because of the growing older populations, there can be a rise in the incidence of secondary spontaneous pneumothorax (SSP) because it typically happens in older populations, mostly with accompanying health conditions. Thus, the market segment is expected to hold the largest market share in the forecast period.
|
Type |
|
|
Treatment |
|
|
Diagnosis |
|
|
End-User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportPneumothorax Treatment Industry Regional Synopsis
North America Market Forecast
North America industry is predicted to dominate majority revenue share of 36% by 2037. The market growth in the region is also expected on account of the rising prevalence of pneumothorax due to the rise in chronic lung disease. Based on research, 2.28 million Canadians have asthma, placing the nation among those with the highest asthma prevalence globally. Furthermore, asthma and COPD are among the chronic lung diseases that affect approximately 34 million Americans. Moreover, high awareness of pneumothorax infection and easy availability of hospitals and medical centers in the region results, in more people likely to choose early diagnosis and treatment, fueling the market growth in the region. Additionally, the region's expanding healthcare sector and increasing expenditures in healthcare are also expected to propel the market's expansion in the years to come.
APAC Market Analysis
The Asia Pacific pneumothorax treatment market is estimated to be the second largest, registering a share of about ~21% by the end of 2037. The market’s expansion can be attributed majorly to the rising awareness about respiratory health and the burgeoning prevalence of lung-related diseases in the region. According to research, about 65 million individuals in India, and around 100 million individuals in China suffer from chronic obstructive pulmonary disease (COPD), which makes up nearly 25% of all COPD cases worldwide. This high incidence of lung-related diseases can be attributed to the unhealthy lifestyle, high pollution rates, and high number of smoking population in the region. In addition, the presence of major market players in developing countries like China India Japan, & the Philippines and government programs aimed at enhancing healthcare access across the region are anticipated to fuel pneumothorax treatment market expansion over the projected period.
Top Featured Companies Dominating the Pneumothorax Treatment Landscape.
- Medtronic
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Angiotech
- BetaGlue
- Teleflex Incorporated
- Abbott
- Smith’s Group plc
- ATMOS MedizinTechnik GmbH & Co. KG
- Sinapi Biomedical
- Nobelpharma Co., Ltd
- Vygon
In the News
- 27 March 2024 - Medtronic plc (NYSE: MDT), a leading global supplier of medical technology, announced that the EvolutTM FX+ transcatheter aortic valve replacement (TAVR) system has received FDA approval in the US for the treatment of symptomatic severe aortic stenosis. The most recent Evolut FX+ TAVR system is intended to make coronary access easier while preserving the valve performance advantages of the previous Evolut TAVR platform.
- 31st January 2024 - The world leader in science-based nutrition, Abbott (NYSE: ABT), has announced the introduction of its new PROTALITYTM brand. The first product in this range to cater to the increasing number of adults who want to lose weight without sacrificing healthy nutrition and muscle mass is the high-protein nutrition smoothie.
Author Credits: Radhika Pawar
- Report ID: 5995
- Published Date: Jan 03, 2025
- Report Format: PDF, PPT
